Strategy analysis

Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – US

An interview with a US key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.

November 9, 2018

Hemophilia KOL Interview – UK

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed drugs, and late-phase pipeline therapies for hemophilia, including alternative coagulation promoters and gene therapies. Unmet needs are also discussed. The main marketed products covered include Hemlibra, Advate, BeneFIX, and Eloctate, and key pipeline assets highlighted are valoctocogene roxaparvovec (valrox), fitusiran, and concizumab.

March 20, 2020

Key Trends in BRICMIST Market Access

Brazil, Russia, India, China, Mexico, Indonesia, South Korea, and Turkey – known collectively as the BRIC/MIST countries – have been a source of welcome growth for a pharmaceutical industry struggling to generate significant gains in its traditional core markets.

October 17, 2016

Head and Neck Cancer KOL Interview – US, Southeast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for head and neck cancer. Disease stratification by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key pipeline assets highlighted include Imfinzi, Bavencio, tremelimumab, and Tecentriq.

April 14, 2020

Latest Trends in Orphan Drug Pricing and Reimbursement

It is now some 35 years since the passage of the first law designed specifically to encourage investment in the discovery and development of rare disease treatments. Activity in the sector has been transformed since then.

February 1, 2018

France Healthcare System Overview

France spent more of its gross domestic product (GDP) on healthcare in 2010 than the average of other key developed markets.

November 2, 2016

Ovarian Cancer Pulse Survey

Diagnostics/diagnostic techniques discussed:

etarfolatide/folic acid, BRCA mutation testing

May 7, 2014

India Pricing and Reimbursement

Affordability of healthcare is a serious challenge for the majority of the population in India. The lack of properly funded and effective public health services drives a large number of people to receive health services from the private sector.

November 4, 2016

Post-ADPD Alzheimer’s Disease KOL Interview

Key Highlights BIIB-037 Amyloid beta PET data show positive Abeta reduction; cognitive results are not interpretable with such small numbers. (BIIB) BIIB-037 Phase Ib result interpretation may be effected by the ApoE4 dropouts in the treatment arm. (BIIB) MK-8931 and BIIB-037 show sufficient target engagement, but there is no evidence to date that amyloid clearance […]

April 8, 2015

Mid Pharma Outlook

$3,000.00

Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth.

September 28, 2016

Datamonitor Healthcare Systemic Lupus Erythematosus KOL Interviews

Datamonitor Healthcare interviewed two experts on systemic lupus erythematosus (SLE) based in the US to gauge their views on currently available treatment options, pipeline drugs and challenges with clinical trial design in SLE.

August 18, 2017

ADPD Alzheimer’s Disease Pulse

Overview We performed a 5-question survey of 25 neurologists in the US to gauge current familiarity with Alzheimer’s Disease (AD) biomarkers and drugs in clinical development for disease modification. Drugs covered include: BIIB037/BART (BIIB), Solanezumab (LLY), Pioglitazone (Takeda), BAN2401 (ESALY/BIIB), MK-8931 (MRK).

March 19, 2015

Datamonitor Psoriatic Arthritis KOL Interviews

Datamonitor interviewed three rheumatologists, two based in the US and one in the UK, to determine their current treatment practices and views on pipeline and marketed drugs for psoriatic arthritis. The three interviews were combined into a single report.

December 12, 2016